BioCryst Pharmaceuticals Inc (MEX:BCRX)
MXN 170 0 (0%) Market Cap: 32.46 Bil Enterprise Value: 43.04 Bil PE Ratio: 0 PB Ratio: 0 GF Score: 53/100

BioCryst Pharmaceuticals Inc to Discuss the Phase 1 trial of BCX9930 - Conference Call Transcript

Oct 28, 2019 / 12:30PM GMT
Operator

Ladies and gentlemen, thank you for standing by, and welcome to the BioCryst Pharmaceuticals Update Call. (Operator Instructions) Please be advised that today's conference is being recorded. (Operator Instructions)

I would now like to turn your call over to John Bluth of BioCryst. You may begin.

John D. Bluth
BioCryst Pharmaceuticals, Inc. - SVP of IR & Corporate Communications

Thank you very much, Kevin. Good morning, and welcome to our call to discuss data from our Phase I trial of BCX9930. Today's press release and accompanying slides, which include data from the Phase I trial in healthy volunteers, are available on our website.

Participating on the call with me today are CEO, Jon Stonehouse; and Chief Medical Officer, Dr. Bill Sheridan. Our CFO, Tom Staab; and our Chief Business Officer, Megan Sniecinski, are also here and will be available during our Q&A session.

Before we begin, I want to direct your attention to Slide 2, which discusses our use of forward-looking statements and potential risk factors regarding an

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot